Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xeris Biopharma Holdings (XERS) Non-Current Debt: 2023-2025

Historic Non-Current Debt for Xeris Biopharma Holdings (XERS) over the last 1 years, with Sep 2025 value amounting to $219.5 million.

  • Xeris Biopharma Holdings' Non-Current Debt was N/A to $219.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $219.5 million, marking a year-over-year change of. This contributed to the annual value of $217.0 million for FY2024, which is 13.66% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Non-Current Debt stood at $219.5 million, which was up 0.39% from $218.6 million recorded in Q2 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Non-Current Debt peaked at $219.5 million during Q3 2025, and registered a low of $190.9 million during Q4 2023.
  • For the 3-year period, Xeris Biopharma Holdings' Non-Current Debt averaged around $212.8 million, with its median value being $217.8 million (2025).
  • Data for Xeris Biopharma Holdings' Non-Current Debt shows a peak YoY grew of 13.66% (in 2024) over the last 5 years.
  • Over the past 3 years, Xeris Biopharma Holdings' Non-Current Debt (Quarterly) stood at $190.9 million in 2023, then climbed by 13.66% to $217.0 million in 2024, then reached $219.5 million in 2025.
  • Its Non-Current Debt was $219.5 million in Q3 2025, compared to $218.6 million in Q2 2025 and $217.8 million in Q1 2025.